Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Application of Urinary Volatile Organic Compounds (VOCs) for the Diagnosis of Prostate Cancer.

Gao Q, Su X, Annabi MH, Schreiter BR, Prince T, Ackerman A, Morgas S, Mata V, Williams H, Lee WY.

Clin Genitourin Cancer. 2019 Feb 16. pii: S1558-7673(19)30047-3. doi: 10.1016/j.clgc.2019.02.003. [Epub ahead of print]

PMID:
30853355
2.

Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.

Salido-Guadarrama AI, Morales-Montor JG, Rangel-Escareño C, Langley E, Peralta-Zaragoza O, Cruz Colin JL, Rodriguez-Dorantes M.

Mol Med Rep. 2016 Jun;13(6):4549-60. doi: 10.3892/mmr.2016.5095. Epub 2016 Apr 8.

3.

Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.

Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, Leyten GH, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Van Criekinge W, Schalken JA.

Eur Urol. 2016 Nov;70(5):740-748. doi: 10.1016/j.eururo.2016.04.012. Epub 2016 Apr 20.

PMID:
27108162
4.

Furan and p-xylene as candidate biomarkers for prostate cancer.

Jiménez-Pacheco A, Salinero-Bachiller M, Iribar MC, López-Luque A, Miján-Ortiz JL, Peinado JM.

Urol Oncol. 2018 May;36(5):243.e21-243.e27. doi: 10.1016/j.urolonc.2017.12.026. Epub 2018 Feb 1.

PMID:
29395956
5.

Olfactory detection of prostate cancer by dogs sniffing urine: a step forward in early diagnosis.

Cornu JN, Cancel-Tassin G, Ondet V, Girardet C, Cussenot O.

Eur Urol. 2011 Feb;59(2):197-201. doi: 10.1016/j.eururo.2010.10.006. Epub 2010 Oct 15.

PMID:
20970246
6.

Exhaled-breath Testing for Prostate Cancer Based on Volatile Organic Compound Profiling Using an Electronic Nose Device (Aeonose™): A Preliminary Report.

Waltman CG, Marcelissen TAT, van Roermund JGH.

Eur Urol Focus. 2018 Nov 24. pii: S2405-4569(18)30358-4. doi: 10.1016/j.euf.2018.11.006. [Epub ahead of print]

PMID:
30482583
7.

Urinary Volatile Organic Compounds for the Detection of Prostate Cancer.

Khalid T, Aggio R, White P, De Lacy Costello B, Persad R, Al-Kateb H, Jones P, Probert CS, Ratcliffe N.

PLoS One. 2015 Nov 24;10(11):e0143283. doi: 10.1371/journal.pone.0143283. eCollection 2015.

8.

Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.

Druskin SC, Tosoian JJ, Young A, Collica S, Srivastava A, Ghabili K, Macura KJ, Carter HB, Partin AW, Sokoll LJ, Ross AE, Pavlovich CP.

BJU Int. 2018 Apr;121(4):619-626. doi: 10.1111/bju.14098. Epub 2018 Jan 9.

9.

GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients.

Monteiro M, Moreira N, Pinto J, Pires-Luís AS, Henrique R, Jerónimo C, Bastos ML, Gil AM, Carvalho M, Guedes de Pinho P.

J Cell Mol Med. 2017 Sep;21(9):2092-2105. doi: 10.1111/jcmm.13132. Epub 2017 Apr 4.

10.

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.

Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, Dunn RL, Meyer S, Hodge P, Groskopf J, Wei JT, Chinnaiyan AM.

Eur Urol. 2016 Jul;70(1):45-53. doi: 10.1016/j.eururo.2015.04.039. Epub 2015 May 16.

11.

Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.

Sánchez BE, Aguayo A, Martínez B, Rodríguez F, Marmolejo M, Svyryd Y, Luna L, Muñoz LA, Jiménez MA, Sotomayor M, Vargas V F, Mutchinick OM.

Clin Genitourin Cancer. 2018 Aug;16(4):e867-e877. doi: 10.1016/j.clgc.2018.02.004. Epub 2018 Feb 27.

PMID:
29571584
12.

Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.

Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta JP, McNicholas T, Lughezzani G, Lista G, Larcher A, Bini V, Cestari A, Buffi N, Graefen M, Bosset O, Le Corvoisier P, Breda A, de la Torre P, Fowler L, Roux J, Guazzoni G.

BJU Int. 2013 Aug;112(3):313-21. doi: 10.1111/bju.12217.

13.

A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy.

Zhang W, Ren SC, Shi XL, Liu YW, Zhu YS, Jing TL, Wang FB, Chen R, Xu CL, Wang HQ, Wang HF, Wang Y, Liu B, Li YM, Fang ZY, Guo F, Lu X, Shen D, Gao X, Hou JG, Sun YH.

Prostate. 2015 May;75(6):653-61. doi: 10.1002/pros.22949. Epub 2015 Jan 18.

PMID:
25597901
14.

The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ.

Eur Urol. 2014 Dec;66(6):1109-15. doi: 10.1016/j.eururo.2014.08.011. Epub 2014 Aug 26.

15.

Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.

Louie KS, Seigneurin A, Cathcart P, Sasieni P.

Ann Oncol. 2015 May;26(5):848-64. doi: 10.1093/annonc/mdu525. Epub 2014 Nov 17. Review.

PMID:
25403590
16.
17.

Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer.

Dai L, Li J, Xing M, Sanchez TW, Casiano CA, Zhang JY.

Prostate. 2016 Nov;76(15):1375-86. doi: 10.1002/pros.23217. Epub 2016 Jul 15.

PMID:
27418398
18.

Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers.

Roberts MJ, Richards RS, Chow CW, Doi SA, Schirra HJ, Buck M, Samaratunga H, Perry-Keene J, Payton D, Yaxley J, Lavin MF, Gardiner RA.

Prostate Int. 2016 Sep;4(3):97-102. doi: 10.1016/j.prnil.2016.04.002. Epub 2016 May 5.

19.

Prostate Health Index density improves detection of clinically significant prostate cancer.

Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, Ghabili K, Mamawala M, Agostino J, Carter HB, Partin AW, Sokoll LJ, Ross AE.

BJU Int. 2017 Dec;120(6):793-798. doi: 10.1111/bju.13762. Epub 2017 Feb 6.

20.

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.

Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, Fisch M, Graefen M, Pummer K, Chun FK.

BJU Int. 2012 Jun;109(11):1627-35. doi: 10.1111/j.1464-410X.2011.10584.x. Epub 2011 Sep 21.

Supplemental Content

Support Center